This photo is not a representation of Qfitlia (fitusiran). For illustrative purposes only.
The US Food and Drug Administration approved Qfitlia™ (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with hemophilia A or B with or without factor VIII or IX inhibitors. Qfitlia, the first antithrombin lowering therapy in hemophilia, offers consistent protection with as few as six injections a year. For more information, please read Sanofi’s press release.